Cargando…

Angiotensin receptor blocker drugs and inhibition of adrenal beta-arrestin-1-dependent aldosterone production: Implications for heart failure therapy

Aldosterone mediates many of the physiological and pathophysiological/cardio-toxic effects of angiotensin II (AngII). Its synthesis and secretion from the zona glomerulosa cells of the adrenal cortex, elevated in chronic heart failure (HF), is induced by AngII type 1 receptors (AT(1)Rs). The AT(1)R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lymperopoulos, Anastasios, Aukszi, Beatrix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368669/ https://www.ncbi.nlm.nih.gov/pubmed/28400916 http://dx.doi.org/10.4330/wjc.v9.i3.200

Ejemplares similares

The place of ARBs in heart failure therapy: is aldosterone suppression the key?
por: Markan, Uma, et al.
Publicado: (2019)

Suppression of adrenal βarrestin1-dependent aldosterone production by ARBs: head-to-head comparison
por: Dabul, Samalia, et al.
Publicado: (2015)

Adrenal βarrestin1 targeting for tobacco–associated cardiac dysfunction treatment: Aldosterone production as the mechanistic link
por: Solesio, Maria E, et al.
Publicado: (2019)

Structure–activity relationship study of angiotensin II analogs in terms of β‐arrestin‐dependent signaling to aldosterone production
por: Valero, Thairy Reyes, et al.
Publicado: (2016)

Not all arrestins are created equal: Therapeutic implications of the functional diversity of the β-arrestins in the heart
por: Lymperopoulos, Anastasios, et al.
Publicado: (2019)

Nicotine-induced adrenal beta-arrestin1 upregulation mediates tobacco-related hyperaldosteronism leading to cardiac dysfunction
por: Cora, Natalie, et al.
Publicado: (2020)

Treatment of heart failure with ACE inhibitors and beta-blockers: What is next? Aldosterone receptor antagonists?
por: van der Horst, Iwan C. C., et al.
Publicado: (2007)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
por: Morishita, Yoshiyuki, et al.
Publicado: (2014)

Antagonistic Roles of GRK2 and GRK5 in Cardiac Aldosterone Signaling Reveal GRK5-Mediated Cardioprotection via Mineralocorticoid Receptor Inhibition
por: Maning, Jennifer, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases
por: Kruik-Kollöffel, Willemien J., et al.
Publicado: (2020)

Renin-angiotensin-aldosterone system and kidney interactions in heart failure
por: Ferreira, João Pedro, et al.
Publicado: (2019)

βArrestins in Cardiac G Protein-Coupled Receptor Signaling and Function: Partners in Crime or “Good Cop, Bad Cop”?
por: Lymperopoulos, Anastasios, et al.
Publicado: (2013)

Carvedilol Selectively Stimulates βArrestin2-Dependent SERCA2a Activity in Cardiomyocytes to Augment Contractility
por: Maning, Jennifer, et al.
Publicado: (2022)

The renin–angiotensin–aldosterone-system and right heart failure in congenital heart disease
por: Andersen, Stine, et al.
Publicado: (2016)

Correction: Maning et al. Antagonistic Roles of GRK2 and GRK5 in Cardiac Aldosterone Signaling Reveal GRK5-Mediated Cardioprotection via Mineralocorticoid Receptor Inhibition. Int. J. Mol. Sci. 2020, 21, 2868
por: Maning, Jennifer, et al.
Publicado: (2021)

Implications of renin‐angiotensin‐system blocker discontinuation in acute decompensated heart failure with systolic dysfunction
por: Darden, Douglas, et al.
Publicado: (2019)

Beta-Arrestins in the Treatment of Heart Failure Related to Hypertension: A Comprehensive Review
por: Rakib, Ahmed, et al.
Publicado: (2021)

OR24-03 GRK2 Mediates Beta-Adrenergic Receptor Crosstalk to Enhanced Adrenocortical AngII-Dependent Aldosterone Production
por: Lymperopoulos, Anastasios, et al.
Publicado: (2020)

Implication of Ivabradine in Up-titrating Beta-blocker in a Patient with Advanced Heart Failure
por: Hori, Masakazu, et al.
Publicado: (2020)

Beta-Blockers and Oxidative Stress in Patients with Heart Failure
por: Nakamura, Kazufumi, et al.
Publicado: (2011)

New advances in beta-blocker therapy in heart failure
por: Barrese, Vincenzo, et al.
Publicado: (2013)

Angiotensin receptor blockers in heart failure after the ELITE II trial
por: Willenheimer, Ronnie
Publicado: (2000)

Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy
por: Wang, Weidong, et al.
Publicado: (2020)

Reduction of Proteinuria in a Patient With Primary Aldosteronism by Angiotensin II Receptor Blocker Administration
por: Rikitake, Junjiro, et al.
Publicado: (2022)

Renin‐Angiotensin‐Aldosterone System Inhibitors Are Associated With Favorable Outcomes Compared to Beta Blockers in Reducing Mortality Following Abdominal Aneurysm Repair
por: Elsayed, Nadin, et al.
Publicado: (2023)

An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers
por: Maideen, Naina Mohamed Pakkir, et al.
Publicado: (2022)

The effect of beta-blockers in acute heart failure according to heart rate
por: Kim, Hyun-Jin, et al.
Publicado: (2021)

Angiotensin II induces coordinated calcium bursts in aldosterone-producing adrenal rosettes
por: Guagliardo, Nick A., et al.
Publicado: (2020)

Poor tolerance of beta-blockers by elderly patients with heart failure
por: Yanagisawa, Satoshi, et al.
Publicado: (2010)

Beta Blockers in Heart Failure: More Evidence for an Old Friend
por: Baek, Sang Hong
Publicado: (2018)

Treatment optimization of beta-blockers in chronic heart failure therapy
por: Niriayo, Yirga Legesse, et al.
Publicado: (2020)

Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease
por: Singhania, Namrata, et al.
Publicado: (2020)

Anaemia in Heart Failure Patients, Associated with Angiotensin – Renin – Aldosterone System Altering Medications
por: Jonaitienė, Neda, et al.
Publicado: (2021)

Renin-Angiotensin-Aldosterone System Activation and Diuretic Response in Ambulatory Patients With Heart Failure
por: Amatruda, Jonathan G., et al.
Publicado: (2022)

The effect of taurine supplementation on the renin–angiotensin–aldosterone system of dogs with congestive heart failure
por: Brethel, Sara, et al.
Publicado: (2023)

Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis
por: Turgeon, Ricky D., et al.
Publicado: (2019)

Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022)

Assessment of Oxidative Stress Markers in Hypertensive Patients under the Use of Renin-Angiotensin-Aldosterone Blockers
por: Vazquez-Agra, Nestor, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9eh3at6163bv55cg7064e4dag0